Hallucinogenic/psychedelic drug. Auditive and visual hallucinations, in low doses amphetamine like effects. Changes in visual acuity, loss of concentration. Giggling. In low doses reported to be an aphrodisiac. Effects are heavily dosage dependent, the hallucinogenic effects happening with higher doses.
Loss of coordination, tense muscles, tremors, nausea, fear and/or panic attack, change in body temperature, stomach and bowel aches/symptoms.
Mechanism of action:
Largely unknown, no research in humans. High inter-user variety. 2-CB appears to be a low efficacy 5-HT2a partial agonist or even full antagonist. Possibly an activator of 5-HT2a coupled phospholipase-D pathway. Studies in rats suggest increase in dopamine levels as well. Metabolized by liver hepatocytes resulting in deamination demethylation that produces several products. Oxidative deamination results in the 2-(4-bromo-2,5-dimethoxyphenyl)-ethanol (BDMPE) and 4-bromo-2,5-dimethoxyphenylacetic acid (BDMPAA) metabolites.
Average onset of effects: 45-70 minutes when taken orally, longer when taken on a full stomach. Effects last 4-6 hours.
Substance and dosage:
Powder or pills, taken orally or insufflated. Average pill contains 4-8mg. Recreational dosage 15-25mg, effects in humans expected from 5mg onwards. Lethal dose unknown, cases of up to 100mg have been reported with no apparent harm.
No (neurotoxic) damage has been reported as far as known.